The aim of this study was to analyze the relations between differentiation immunophenotypes and the status of apoptosis and proliferation in diffuse large B-cell lymphomas. Therefore, the bcl6/CD10/MUM1/CD138 differentiation immunophenotypic profiles were studied in relation to (a) the apoptotic index, (b) the apoptosis-associated bcl2 family proteins bcl2, bcl-xl, bax, bak, bad and bid, (c) the proliferation index (Ki67) and (d) the cell cycle proteins cyclin A, cyclin B1, cyclin D3, cyclin E, p53, Rb, p16 and p27 in 79 cases of diffuse large B-cell lymphomas. Two major differentiation immunophenotypic profiles were distinguished: the germinal center B-cell-like profile; 31 cases (bcl6 þ /CD107/MUM1À/CD138À: 29 cases and bcl6À/CD10 þ /MUM1À/ CD138À: two cases) and the nongerminal center B-cell-like profile (bcl67/CD10À/MUM1 þ /CD138À); 48 cases. The expression of bax, bak and bid and the apoptotic index were significantly higher in the germinal center Bcell-like profile than in the nongerminal center B-cell-like profile (P ¼ 0.045, 0.018, 0.003 and 0.034, respectively). In contrast, the expression of bcl-xl was significantly lower in the germinal center B-cell-like profile than in the nongerminal center B-cell-like profile (P ¼ 0.026). The expression of bcl6 and CD10 showed significant positive correlation with the expression of bax (r ¼ 0.659, Po0.001 and r ¼ 0.240, P ¼ 0.033, respectively), bak (r ¼ 0.391, Po0.001 and r ¼ 0.233, P ¼ 0.039, respectively) and bid (r ¼ 0.652, Po0.001 and r ¼ 0.238, P ¼ 0.035, respectively) and significant negative correlation with the expression of bcl-xl (r ¼ À0.536, Po0.001 and r ¼ À0.250, P ¼ 0.029, respectively). The expression of MUM1 showed significant negative correlation with the expression of bax (r ¼ À0.276, P ¼ 0.014) and bid (r ¼ À0.266, P ¼ 0.018) and significant positive correlation with the expression of bcl-xl (r ¼ 0.238, P ¼ 0.037). The above findings indicate that diffuse large B-cell lymphomas with germinal center B-cell-like immunophenotypic profile are associated with increased apoptosis status, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl.
Diffuse large B-cell lymphomas represent the most common type of non-Hodgkin's lymphomas in Western countries and are characterized by heterogeneous clinical, immunophenotypic and genetic features. [1] [2] [3] [4] [5] [6] [7] There is accumulating evidence that diverse mechanisms resulting in the deregulation of cell cycle and apoptotic pathways are involved in the pathogenesis of diffuse large B-cell lymphomas. [3] [4] [5] [6] Recently, the global gene expression profile of diffuse large B-cell lymphomas was analyzed by cDNA [8] [9] [10] and oligonucleotide microarrays. 11 Alizedeh et al 8 identified two molecularly distinct groups of diffuse large B-cell lymphomas, the germinal center B-cell-like and the activated B-celllike diffuse large B-cell lymphomas. This was confirmed by Rosenwald et al 9 who, in addition to the two gene expression groups, also described the type 3 diffuse large B-cell lymphomas. The germinal center B-cell-like diffuse large B-cell lymphomas were characterized by the expression of genes of the normal germinal center B cells (eg bcl6, CD10, CD38), the activated B-cell-like diffuse large B-cell lymphomas were characterized by the expression of genes that are normally induced during in vitro activation of peripheral blood B cells and the type 3 diffuse large B-cell lymphomas did not express either set of genes at a high level. [8] [9] [10] The gene expression signature of the activated B-cell-like diffuse large B-cell lymphomas included a gene that is translocated in lymphoid malignancies, IRF4 (MUM1/LSIRF), antiapoptotic genes such as FLIP and bcl2 and a subset of the genes that are characteristic of plasma cells. [8] [9] [10] The patients with germinal center B-cell-like diffuse large B-cell lymphomas had more favorable clinical outcome than those with activated B-cell-like or type 3 diffuse large B-cell lymphomas. [8] [9] [10] Since the cDNA and oligonucleotide microarrays technology is not generally available, many studies investigated the immunohistochemical expression of B-cell differentiation antigens (eg bcl6, CD10, MUM1, CD138) in diffuse large B-cell lymphomas and some of them correlated the differentiation immunophenotypes with clinical data. Importantly, in one of these studies, Hans et al, 32 showed that the classification of diffuse large B-cell lymphomas into germinal center and nongerminal center B-cell-like groups based on the bcl6/CD10/ MUM1 differentiation immunophenotypes is prognostically relevant and predicts the cDNA classification in 71% of germinal center B-cell-like and 88% of activated B-cell-like or type 3 diffuse large B-cell lymphomas. On the other hand, the expression of bcl6 and CD10 was associated with increased apoptosis and proliferation in cell lines and lymphoid malignancies. [33] [34] [35] [36] [37] [38] [39] [40] In this respect, we recently showed that increased expression of bcl6 and CD10 is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. 41 However, to the best of our knowledge, little is known about the relations between the bcl6/CD10/MUM1/ CD138 differentiation immunophenotypes and the status of apoptosis and proliferation in these lymphomas. In addition, although the immunohistochemical expression of the apoptosis-associated bcl2 family proteins, bcl2, bax, bak and mcl1 was reported in diffuse large B-cell lymphomas, 16, 18, 20, 21, 27, [42] [43] [44] [45] [46] [47] [48] [49] [50] the expression levels of bcl-xl, bad and bid proteins and their relations with the status of apoptosis and proliferation were not extensively analyzed in these lymphomas. Therefore, the bcl6/CD10/MUM1/CD138 differentiation immunophenotypic profiles were studied in relation to (a) the apoptotic index, (b) the apoptosisassociated proteins bcl2, bcl-xl, bax, bak, bad and bid, (c) the proliferation index (Ki67) and (d) the cell cycle proteins cyclin A, cyclin B1, cyclin D3, cyclin E, p53, Rb, p16 and p27 in 79 cases of diffuse large B-cell lymphomas.
Materials and methods

Materials
In all, 79 cases of de novo diffuse large B-cell lymphomas (37 nodal and 42 extranodal) classified according to the WHO classification 1 were selected from the files of the Department of Pathology of the University of Ioannina on the basis that complete clinicopathological parameters were available.
Immunohistochemistry
Immunostainings were performed on formalinfixed, paraffin-embedded tissue sections by the labelled streptavidin-avidin-biotin method using monoclonal antibodies directed against CD138 (dilution 1:10, clone AM411-10 M, BioGenex, CA, USA), bcl-xl (dilution 1:25, clone 2H11, Zymed, South San Francisco CA, USA) and bad (dilution 1:40, clone sc-8044, Santa Cruz, CA, USA). In addition, the following polyclonal antibodies were used: bax (dilution 1:40, code A3533, Dako SA, Glostrup, Denmark), bak (dilution 1:40, code A3538, Dako SA, Glostrup, Denmark), bid (dilution 1:40, clone sc-11423, Santa Cruz, CA, USA) and IRF-4/MUM1 (dilution 1:40, clone sc-6059, Santa Cruz, CA, USA). Pretreatment of the sections with 10 mM sodium citrate buffer (pH 6.0) in a microwave oven was performed. The monoclonal antibodies directed against bcl6, CD10, bcl2, Ki67, cyclin A, cyclin B1, cyclin D3, cyclin E, p53, Rb1, p16 and p27 proteins, the corresponding positive controls and the counting approach for the expression status of these proteins were reported in detail previously. 41, 51, 52 The same approach was used for the counting of MUM1, CD138, bax, bak, bad, bid and bcl-xl immunopositive cells. Briefly, a continuous score system was adopted by using the Â 40 objective lens and counting at least 10 fields selected on the basis that they contained immunopositive cells. The number of immunopositive cells was divided by the total number of the counted cells and the expression was defined as the percentage of positive cells in the total number of the counted cells. Positive expression for MUM1 and CD138 proteins was considered when at least 25% of neoplastic cells were immunopositive according to previous criteria. 12 The bcl6/CD10/MUM1/CD138 immunophenotypes and their assignment to germinal center or nongerminal center B-cell-like profiles were determined taking into consideration previous criteria. 32 Positive expression for bcl-xl, bax, bak, bad and bid proteins was considered when at least 10% of neoplastic cells were immunopositive.
Reactive lymph nodes and normal thymuses from our previous studies were used as positive controls. 41, 51, 52 Negative controls were included and consisted in the same immunohistochemical method with omission of the primary antibody. The immunohistochemical expression of bcl6, CD10, bcl2, cyclin A, cyclin B1, cyclin D3, cyclin E, p53, Rb, p16 and p27 proteins, the proliferation index (as assessed by the Ki67 staining) and the apoptotic index (as assessed by the TUNEL method) were reported in detail previously.
Statistical Analysis
Mann
41,51,52
Differentiation Immunophenotypic Profiles
Two major immunophenotypic profiles were distinguished according to the pattern of differentiation: (a) the germinal center B-cell-like differentiation immunophenotypic profile; 31 cases (bcl6 þ / CD10 þ /MUM1À/CD138À: 26 cases, bcl6 þ / CD10À/MUM1À/CD138À: three cases and bcl6À/ CD10 þ /MUM1À/CD138À: two cases) and (b) the nongerminal center B-cell-like differentiation immunophenotypic profile; 48 cases (bcl6 þ /CD10À/ MUM1 þ /CD138À: 24 cases and bcl6À/CD10À/ MUM1 þ /CD138À: 24 cases) ( Table 2) .
Relations between the Two Major Differentiation Immunophenotypic Profiles and Apoptotic Index, Proliferation Index, bcl2 Family Proteins and Cell Cycle Proteins
The Mann-Whitney test was used to analyze the two major bcl6/CD10/MUM1/CD138 differentiation immunophenotypic profiles in relation to the apoptotic index, the proliferation index (Ki67) and the expression levels of bcl2 family proteins and cell cycle proteins (Table 3 ). The germinal center B-celllike profile, compared to the nongerminal center B-cell-like profile, was significantly associated with higher apoptotic index (P ¼ 0.034), higher expression of bax (P ¼ 0.045), bak (P ¼ 0.018) and bid (P ¼ 0.003) proteins and lower expression of bcl-xl protein (P ¼ 0.026) ( Table 3) . No significant correlations were found between the two major bcl6/CD10/ MUM1/CD138 differentiation immunophenotypic profiles and the expression levels of bcl2, bad, 
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Ki67, cyclin A, cyclin B1, cyclin D3, cyclin E, p53, Rb, p16 and p27 proteins ( Table 3 ). The basic statistical data (mean values, standard deviation, standard error, range) for the expression levels of the bcl2 family proteins and for the values of the apoptotic index in relation to the two major bcl6/ CD10/MUM1/CD138 differentiation immunophenotypic profiles are presented in Table 4 . The relations between the expression of bcl2 family proteins (positive vs negative cases) and the two major bcl6/CD10/MUM1/CD138 differentiation immunophenotypic profiles are presented in Table 5 .
The w 2 tests were used to analyze the two major bcl6/CD10/MUM1/CD138 differentiation immunophenotypic profiles in relation to the expression status (high-vs low-expression status) of bcl2 family proteins, cell cycle proteins and the proliferation index (Ki67). The germinal center B-cell-like profile was significantly associated with high-expression status of bak (P ¼ 0.036) and bid (P ¼ 0.001) proteins and low expression status of bcl-xl protein (P ¼ 0.031) ( Table 6 ). No significant correlations were found between the two major bcl6/CD10/ MUM1/CD138 differentiation immunophenotypic profiles and the expression status (high-vs lowexpression status) of bcl2, bax, bad, Ki67, cyclin A, cyclin B1, cyclin D3, cyclin E, p53, Rb, p16 and p27 proteins (data not shown).
Relations between bcl6, CD10 and MUM1 Proteins and bcl2 Family Proteins
The Spearman correlation coefficient test (for assessment of correlation between two continuous variables) was used to analyze the relations of bcl6, CD10 and MUM1 proteins with bcl2 family proteins and the relations between MUM1, proliferation index and apoptotic index ( Table 7) . The relations between bcl6, CD10, proliferation index and apoptotic index were reported previously. 41 The positive or negative sign of the Spearman correlation coefficient r in Table 7 Table 7) . 
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Relations between bcl2 Family Proteins, Apoptotic Index and Proliferation Index
The Spearman correlation coefficient test was used to analyze the relations between bcl2 family proteins, apoptotic index and proliferation index (Ki67) ( Table 8 ). The positive or negative sign of the Spearman correlation coefficient r in Table 8 (Table 8) .
Correlation with Clinicopathological Parameters
Using w 2 tests, no significant correlation was found between tumor localization (nodal vs extranodal) or tumor stage (I-IV) and the two major bcl6/CD10/ MUM1/CD138 differentiation immunophenotypic profiles (data not shown).
Discussion
In the present study, we analyzed the relations between the bcl6/CD10/MUM1/CD138 differentiation immunophenotypic profiles and the status of apoptosis and proliferation in diffuse large B-cell lymphomas. In addition, we analyzed the expression patterns of the bcl2 family proteins bcl2, bcl-xl, 
Po0.001* r, Spearman's correlation coefficient. The positive or negative sign of the Spearman's correlation coefficient r expresses significant (Po0.05) or nonsignificant (P ¼ 0.05 or P40.05) positive or negative correlations between two continuous variables. *indicates the statistically significant correlations (Po0.05).
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In the present study, we found that in diffuse large B-cell lymphomas the germinal center B-cell-like differentiation immunophenotypic profile was significantly correlated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. In addition, the expression of the germinal center B-cell-related bcl6 and CD10 proteins showed significant positive correlation with bax, bak and bid expression and significant negative correlation with bcl-xl expression. Furthermore, we recently reported that the expression of bcl6 and CD10 proteins showed significant positive correlation with apoptotic index. 41 The aforementioned results, taken together, may be related to findings in various cell lines and lymphoid malignancies suggesting that the expression of the proteins bcl6 and CD10 is associated with increased apoptosis. [33] [34] [35] [36] [37] [38] [39] [40] With respect to the relation between bcl6 and apoptosis, of particular interest are the in vitro studies of Yamochi et al 35 and Tang et al. 36 Indeed, Yamochi et al 35 showed that bcl6 overexpression induced apoptosis of CV1 and HeLa cells which was preceded by downregulation of the antiapoptotic genes bcl2 and bcl-xl. In addition, Tang et al 36 showed that the forkhead transcription factor AFX activates apoptosis by induction of bcl6 which directly binds to and suppresses the promoter of bcl-xl. These findings suggest that the significantly lower expression of the antiapoptotic protein bcl-xl that we found in diffuse large B-cell lymphomas with germinal center B-cell like immunophenotypic profile may be due, at least in part, to downregulation of bcl-xl expression induced by bcl6 overexpression. 36 With respect to the relation between CD10 and apoptosis, it was suggested that CD10 might degrade cytokines that could play a protective role in B-and T-cell apoptosis. 38 This activity may be consistent with the capacity of CD10 to hydrolyze a variety of active peptides, including growth and chemotactic factors. 38 Thus, it is possible that CD10 participates in the process of selection in the germinal center and the thymus by increasing the threshold of cytokines required to prevent B-and T-cell apoptosis, respectively. 38 In the present study, we found that in diffuse large B-cell lymphomas the nongerminal center B-celllike differentiation immunophenotypic profile was significantly associated with low apoptotic index, low expression of the proapoptotic proteins bax, bak and bid and high expression of the antiapoptotic protein bcl-xl. In addition, the expression of the MUM1 protein, which is a main feature of the nongerminal center B-cell-like immunophenotypic profile, 12, 32 showed significant negative correlation with bax and bid expression and significant positive correlation with bcl-xl expression. The aforementioned results, taken together, may be related to findings that activated (nongerminal) diffuse large B-cell-like lymphomas are characterized by constitutive nuclear factor-Kappa B activity which may upregulate many antiapoptotic nuclear factor-Kappa B target genes such as bcl2, bcl-xl, A1, TRAF1, TRAF2, c-IAP1 and c-IAP2. 33, 53 These findings suggest that the significantly higher expression of the antiapoptotic protein bcl-xl that we found in diffuse large B-cell lymphomas with nongerminal center B-cell-like immunophenotypic profile may be due, at least in part, to upregulation of bcl-xl expression induced by the constitutive nuclear factor-Kappa B activity. 33 In addition, the IRF4 (MUM1/LSIRF) gene is also a nuclear factorKappa B target 33, 53, 54 and this may provide an explanation for the significant positive correlation between MUM1 and bcl-xl expression in the present study. IRF4, a transcription factor that is required for the proliferation of B and T lymphocytes, has been suggested to be a mediator of nuclear factorKappa B proliferative responses in activated (nongerminal center) B-cell-like diffuse large B-cell lymphomas. 54 In the present study, we found that diffuse large B-cell lymphomas frequently express bcl2 family proteins: bax in 92%, bak in 52%, bad in 76%, bid in 56% and bcl-xl in 60%. These results, taken together with previous findings 16, 18, 20, 21, 27, [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] showing that diffuse large B-cell lymphomas frequently express bcl2, mcl1, bax and bak proteins, suggest that apoptotic mechanisms mediated by bcl2 family proteins are likely to be involved in the pathogenesis of diffuse large B-cell lymphomas. Interestingly, the present and previous findings 16, 18, 20, 21, 27, [42] [43] [44] [45] [46] [47] [48] [49] [50] indicate that the expression of bcl2 family proteins is variable and heterogeneous in diffuse large B-cell lymphomas. This is likely to reflect differentially regulated expression of bcl2 family proteins, which may be related to abnormalities in gene structure and/or expression. It is known that variations of bcl2 expression in a part of diffuse large B-cell lymphomas may be ascribed to t(14;18) of bcl2 to IgH locus or to amplification of the bcl2 gene genomic locus. [3] [4] [5] [6] 14, 16, 21 The variations in bax, bak and bcl-xl expression in diffuse large B-cell lymphomas may not be related to underlying gene mutations since they were rare in these tumors. 50, 55, 56 Interestingly, bad-deficient mice develop, with aging, diffuse large B-cell lymphomas of germinal center origin 57 suggesting a putative role of bad in the pathogenesis of these neoplasias. Further studies are required to gain insight into the regulation of the expression of the bcl2 family proteins in diffuse large B-cell lymphomas.
In the present study, we found that the apoptotic index was positively correlated with the expression of the proapoptotic proteins bax, bak, bad and bid and negatively correlated with the expression of the antiapoptotic proteins bcl2 and bcl-xl. Thus, the differential expression of bcl2 family proteins may provide an explanation, at least in part, for the variations of the apoptotic index observed in diffuse Differentiation phenotypes and apoptosis in diffuse large B-cell lymphomas M Bai et al large B-cell lymphomas. 41 In addition, the proliferation index (Ki67) was positively correlated with the apoptotic index and the expression of the proapoptotic proteins bax, bak, bad and bid and negatively correlated with the expression of the antiapoptotic proteins bcl2 and bcl-xl. These results are in keeping with previous findings that apoptotic and proliferative indices are positively correlated in B-cell lymphomas 42, 58 and with recent data that bcl-xl and bcl2 inhibit cell proliferation. 59, 60 Interestingly, the antiproliferative effects of bcl-xl and bcl2 were related to their ability to enhance G (0) arrest thereby contributing to cell cycle delay in G (0)-G (1) transition. 59 Thus, it was suggested that the cell cycle effects result from intrinsic functions of bcl-xl and bcl2. 59 Furthermore, other apoptosisassociated bcl2 family proteins such as mcl1 may be involved in the regulation of cell proliferation and differentiation by sustaining or inhibiting cell viability at critical points of the cell cycle (review in Craig 61 ). The relations between differentiation immunophenotypic profiles and apoptosis status may be relevant to the clinical behavior of diffuse large B-cell lymphomas. Indeed, recent studies reported that (a) the 5-year survival of diffuse large B-cell lymphomas with germinal center B-cell-like immunophenotypic profile was better than that of diffuse large B-cell lymphomas with nongerminal center Bcell-like immunophenotypic profile 20, 32 and (b) the immunoexpression of bcl6 or CD10 proteins was associated with better overall survival whereas expression of MUM1 protein was associated with worse overall survival in diffuse large B-cell lymphomas. 8, 13, 22, 28, 32 In addition, high bax immunoexpression, which was associated with the germinal center B-cell-like immunophenotypic profile in the present study, was found to be related to better 5-year overall survival in diffuse large B-cell lymphomas. 48 On the basis of the above results, it could be hypothesized that germinal center B-celllike diffuse large B-cell lymphoma may be more susceptible to apoptosis and, as a consequence, may be more sensitive to treatment.
In conclusion, the present study indicates that diffuse large B-cell lymphomas with germinal center B-cell-like immunophenotypic profile are associated with increased apoptosis status, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. In contrast, diffuse large B-cell lymphomas with nongerminal center B-cell-like immunophenotypic profile are associated with decreased apoptosis status, low expression of the proapoptotic proteins bax, bak and bid and high expression of the antiapoptotic protein bcl-xl. In view of previous results 20, 32 showing that the expression of the germinal center B-cell-like differentiation immunophenotypic profile is associated with favorable clinical outcome, it could be hypothesized that germinal center B-celllike diffuse large B-cell lymphoma may be more susceptible to apoptosis and, as a consequence, may be more sensitive to treatment.
